Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AB Science SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
AB Science SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
AB Science SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
AB Science SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
AB Science SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
AB Science SA, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
AB Science to Raise USD16.2 Million in Private Placement of Shares 11
AB Science Raises USD8 Million in Public Offering of Shares 12
AB Science Raises USD13.5 Million in Private Placement of Shares 13
Debt Offering 15
AB Science Completes Private Placement Of Bonds Due 2019 For US$13 Million 15
AB Science SA – Key Competitors 16
AB Science SA – Key Employees 17
AB Science SA – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Financial Announcements 19
Aug 31, 2017: AB Science: Revenue Report For First Half of 30 June 2017 19
Aug 31, 2017: AB Science reports its revenue for the first half of 2017 23
May 01, 2017: AB Science Reports its Annual Financials as of 31 December 2016 and Provides an Update on its Activities 29
Aug 31, 2016: AB Science: First half of 2016 results 36
Apr 29, 2016: AB Science announces annual financial results as of 31 December 2015 41
Legal and Regulatory 47
Jul 14, 2016: Action plan following warning letter has been validated by FDA 47
Product News 48
07/11/2016: FDA approves first compassionate use of masitinib in amyotrophic lateral sclerosis 48
07/04/2016: Review of the conditional marketing authorization application of masitinib in amyotrophic lateral sclerosis (ALS) will follow the standard timeline of the European Medicines Agency (EMA) 49
05/18/2017: AB Science Announces Refusal of the marketing authorisation for Masipro (masitinib) 50
05/17/2017: AB Science announces that CHMP has adopted a negative opinion for masitinib in indolent systemic mastocytosis, primarily due to GCP inspection findings 51
04/11/2016: Masitinib in Amyotrophic Lateral Sclerosis (ALS) 53
03/20/2017: AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis 56
03/10/2016: AB Science : New independent publications underscore the potential of masitinib in neurological and neurodegenerative diseases 58
Product Approvals 59
Sep 29, 2016: AB Science Announces the Filing of Masitinib in the Treatment of Amyotrophic Lateral Sclerosis (ALS) to the European Medicines Agency 59
Aug 08, 2016: AB Science Announces that Masitinib Receives from European Medicines Agency (EMA) Orphan Drug Designation in the European Union for Amyotrophic Lateral Sclerosis 60
Jun 06, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended the filing of masitinib in ALS for conditional marketing authorization 61
May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis 62
Feb 01, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended to file a marketing authorization application for full approval for masitinib in severe systemic mastocytosis 63
Clinical Trials 65
May 18, 2017: AB Science Presents Phase 3 Data for Masitinib in Amyotrophic Lateral Sclerosis at the European Network For The Cure of ALS Annual Meeting 65
May 12, 2017: AB Science announces that ANSM requested the temporary suspension of clinical studies conducted in France following deviations from Good Clinical Practice standards 67
Mar 29, 2017: AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years 69
Mar 07, 2017: AB Science Announces That Frontiers In Aging Neuroscience Publishes A Comprehensive Review On The Future Potential Of Masitinib In Amyotrophic Lateral Sclerosis 70
Mar 06, 2017: AB Science announces completion of patient recruitment for phase 3 study in severe persistent asthma 71
Jan 09, 2017: AB Science announces publication in The Lancet of phase 3 clinical trial results demonstrating masitinib is effective and well tolerated in the treatment of adult patients with severe indolent systemic mastocytosis 72
Jan 03, 2017: New Preclinical Data Demonstrate That Masitinib Has An Unexpected Protective Effect On Muscles And Nerves In Amyotrophic Lateral Sclerosis 74
Dec 01, 2016: AB Science will present phase 3 results in severe s ystemic mastocytosis at the Journées Dermatologiques de Paris 2016 76
Oct 03, 2016: AB Science has been invited at four international meetings to present new preclinical data showing neuroprotective effect of masitinib in amyotrophic lateral sclerosis (ALS) 77
Jul 11, 2016: AB Science Announces The Publication In The Journal Of Neuroinflammation Of Preclinical Data Showing Neuroprotective Effect Of Masitinib In Amyotrophic Lateral Sclerosis 79
May 30, 2016: AB Science will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21St Congress of the European Hematology Association 81
Apr 06, 2016: AB Science Will Host Live Webcast On Phase 3 Interim Analysis In ALS On 8 April 2016, 83
Apr 04, 2016: Ab Science Announces Positive Interim Results From Phase 3 Trial Of Masitinib In Amyotrophic Lateral Sclerosis 85
Mar 02, 2016: AB Science will present new preclinical and clinical data at the International Symposium on Advances in Alzheimer Therapy (ATT 2016) 87
Appendix 89
Methodology 89
About GlobalData 89
Contact Us 89
Disclaimer 89
AB Science SA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
AB Science SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
AB Science SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
AB Science SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
AB Science SA, Deals By Therapy Area, 2011 to YTD 2017 9
AB Science SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
AB Science to Raise USD16.2 Million in Private Placement of Shares 11
AB Science Raises USD8 Million in Public Offering of Shares 12
AB Science Raises USD13.5 Million in Private Placement of Shares 13
AB Science Completes Private Placement Of Bonds Due 2019 For US$13 Million 15
AB Science SA, Key Competitors 16
AB Science SA, Key Employees 17
AB Science SA, Subsidiaries 18
